ReviewCureus2025
Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Changes in NT-proBNP Levels According to SGLT2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure Decompensation: A Prospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) represents a growing clinical challenge with limited therapeutic options. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as a promising intervention; however, their impact across diverse HFpEF populations requires further clarification. We conducted a systematic review of four completed randomized controlled trials (RCTs) - CANDLE (Canagliflozin Anti-inflammatory and Metabolic Effects), EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction), the JCI 2021 Empagliflozin HFpEF trial (a Japan Cardiovascular Initiative study assessing empagliflozin in heart failure with preserved ejection fraction), and a multi-agent SGLT2 inhibitor study (empagliflozin, dapagliflozin, and canagliflozin vs. standard of care) - plus one ongoing multicenter study, HELD-HF (Heart Failure with Preserved Ejection Fraction and Empagliflozin in a Long-term Diabetes Population), encompassing approximately 13,400 participants with HFpEF, to evaluate the efficacy and safety of SGLT2 inhibition. In EMPEROR-Preserved (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.